摘要
在我国,食道癌是癌症死亡的第四大最常见的原因,严重威胁人类的健康。手术是食管癌治疗的重要方式,但对于不可手术的进展期食管癌患者,放化疗是其标准的治疗方式。然而目前的治疗方式预后仍然欠佳。因此,有必要开发更有效的新药融入该综合治疗模式中。靶向药物联合放疗在头颈部肿瘤治疗中已被证实能使患者获益。本综述集中阐述了在食管癌治疗中靶向药物的安全性及有效性,同时指出靶向药物与放射治疗相结合显示了良好的耐受性及令人满意的近期疗效,值得更深入的临床试验进一步研究。
In China,esophageal cancer is the fourth most common cause of cancer death,which has a serious threat to human health.Surgery is the cornerstone in treatment for esophageal cancer,and chemoradiotherapy is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma who are unsuitable for surgery. However,prognosis for these patients remains poor. Thus,there is a necessity to integrate more effective novel drugs into the multimodal treatment. A benefit of targeted therapy has been shown in head and neck cancer in combination with radiotherapy. This review focuses on the safety and efficacy of targeted drug in the treatment of esophageal cancer,and points out that targeted drug combined with radiation therapy displays a good tolerance and a satisfactory short- term effect. Further clinical trial of targeted drug plus radiation for patients with esophageal cancer needs to be carried out.
出处
《安徽医药》
CAS
2016年第7期1225-1229,共5页
Anhui Medical and Pharmaceutical Journal
关键词
食管肿瘤
化放疗
分子靶向治疗
Esophageal Neoplasms
Chemoradiotherapy
Molecular Targeted Therapy
